Rhythm Pharmaceuticals (RYTM) Income from Non-Controlling Interests (2020 - 2026)

Rhythm Pharmaceuticals' (RYTM) quarterly Income from Non-Controlling Interests came in at -$544000.0 in Q1 2026, down 5340.0% year-on-year from $10381.7 in Q1 2025, and down 5340.0% on a QoQ basis from -$10000.0 in Q1 2025.

Rhythm Pharmaceuticals (RYTM) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends

Rhythm Pharmaceuticals (RYTM) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$544000.0 in Q1 2026.

  • On a quarterly basis, Income from Non-Controlling Interests fell 5340.0% year-over-year to -$544000.0 in Q1 2026; TTM through Mar 2026 was -$1.1 million, a 4629.17% decrease from a year earlier, with the FY2025 full-year figure at $504000.0, up 388.0% from the prior year.
  • Income from Non-Controlling Interests for Q1 2026 stood at -$544000.0, down from -$10000.0 in the prior quarter.
  • Over the last five years, Income from Non-Controlling Interests for RYTM reached as high as -$10000.0 in Q1 2025 and fell as low as -$544000.0 in Q1 2026.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Rhythm Pharmaceuticals 6.98 Bn 6.64 Bn 52.96 Mn -544,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -544,000.00
Mar 31, 2025 -10,000.00
Dec 31, 2020 -189,000.00
Sep 30, 2020 -392,000.00
Jun 30, 2020 567,000.00
Mar 31, 2020 63,000.00